Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | PHGDH | O43175 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 4/20 | 0.41 |
| ▸ | CA1 | P00915 | 4/20 | 0.41 |
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | CA9 | Q16790 | 4/20 | 0.41 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4925822 | 0.91 | S1PR2 (0.46) | MAPTKMT2AL3MBTL1MAPK1S1PR2 | |
| Supinoxin SCHEMBL1137972 | 0.91 | S1PR2 (0.46) | MAPTKMT2AL3MBTL1MAPK1S1PR2 | |
| Supinoxin SCHEMBL29422967 | 0.91 | S1PR2 (0.46) | MAPTKMT2AL3MBTL1MAPK1S1PR2 | |
| SCHEMBL4926171 | 0.91 | GAA (0.55) | MAPTKMT2AMAPK1LMNAGAA | |
| SCHEMBL4925320 | 0.90 | PHGDH (0.46) | MAPTKMT2AL3MBTL1MAPK1LMNA | |
| SCHEMBL4931896 | 0.90 | PDGFRB (0.49) | MAPTKMT2AL3MBTL1MAPK1GAA | |
| SCHEMBL4925380 | 0.89 | MAPT (0.46) | MAPTKMT2AL3MBTL1MAPK1LMNA | |
| SCHEMBL4920688 | 0.89 | KMT2A (0.50) | MAPTKMT2AL3MBTL1MAPK1LMNA | |
| SCHEMBL4928471 | 0.89 | MAPT (0.46) | MAPTKMT2AL3MBTL1MAPK1LMNA | |
| SCHEMBL4930408 | 0.89 | PHGDH (0.40) | MAPTKMT2AL3MBTL1MAPK1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103524436-A | 1-[(3-alkoxy-6-substituted-quinoxalin-2-yl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives | REXAHN PHARMACEUTICALS INC | 2014-01-22 | — | — | CN | disclosed |
| US-8598173-B2 | 1-[(6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives for treating tumors | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2013-12-03 | — | — | US | disclosed |
| US-20130053390-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | REXAHN PHARMACEUTICALS, INC. | 2013-02-28 | — | — | US | disclosed |
| US-8314100-B2 | 1-[6,7-substituted alkoxyquinoxalinyl)aminocarbonyl]-4-(hetero)arylpiperazine derivatives | REXAHN PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20080318963-A1 | 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives | REXAHN PHARMACEUTICALS, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| EP-1819698-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | Rexahn Pharmaceuticals, Inc. (US) | 2007-08-22 | — | — | EP | disclosed |
| WO-2006054830-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | REXAHN PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318963-A1 | 1-[6,7-Substituted Alkoxyquinoxalinyl) Aminocarbonyl]-4-(Hetero) Arylpiperazine Derivatives | HRAS, CDK4, KRAS | MAPT 4614/4885KMT2A 549/4885L3MBTL1 3490/4885 |
| US-20130053390-A1 | 1-[(6,7-SUBSTITUTED ALKOXYQUINOXALINYL)AMINOCARBONYL]-4-(HETERO)ARYLPIPERAZINE DERIVATIVES | HRAS, CDK4, KRAS | MAPT 4577/4885KMT2A 814/4885L3MBTL1 3605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.